Loading
A phase 2 trial of Fulvestrant and Tinengotinib in HR-positive / HER2-negative breast cancer, run by TransThera Sciences (Nanjing), Inc., now recruiting.
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment is a phase 2 interventional study registered as NCT07498478 by TransThera Sciences (Nanjing), Inc., with 94 participants planned, started 2026-03-17 and due to reach its primary completion in 2027-06-30. Interventions recorded: Tinengotinib at the optimal dose combined with Fulvestrant, Tinengotinib and tinengotinib combined with fulvestrant.
Shares TransThera Sciences, Tinengotinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Small-molecule kinase inhibitors and the tag pipeline.